½ÃÀ庸°í¼­
»óǰÄÚµå
1319878

¼¼°èÀÇ µ¿¹° ÀÇ·á¿ë ´ÜŬ·ÐÇ×ü ½ÃÀå Á¶»ç º¸°í¼­ : »ê¾÷ ºÐ¼®, ±Ô¸ð, Á¡À¯À², ¼ºÀå, µ¿Çâ ¹× ¿¹Ãø(2023-2030³â)

Global Monoclonal Antibodies In Veterinary Health Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2023 to 2030

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Value Market Research | ÆäÀÌÁö Á¤º¸: ¿µ¹® 175 Pages | ¹è¼Û¾È³» : 1-2ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

µ¿¹° ÀÇ·á¿ë ´ÜŬ·ÐÇ×ü ½ÃÀåÀÇ ¼¼°è ¼ö¿ä´Â 2022³â 7¾ï 1,809¸¸ ´Þ·¯¿¡¼­ 2030³â¿¡´Â 27¾ï 4,158¸¸ ´Þ·¯¿¡ À°¹ÚÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, 2023³â-2030³â Á¶»ç±â°£ µ¿¾È 18.23%ÀÇ ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR)À» ³ªÅ¸³¾ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

µ¿¹° ÀÇÇп¡¼­ ´ÜŬ·ÐÇ×ü(mAbs)´Â ´Ù¾çÇÑ Áúº´°ú ÁúȯÀ» Ä¡·áÇϱâ À§ÇØ µ¿¹°¿¡°Ô »ç¿ëµÇ´Â Ç¥ÀûÄ¡·áÁ¦ÀÇ ÀÏÁ¾ÀÔ´Ï´Ù. À̵éÀº ¸é¿ª°è°¡ °¨¿°À̳ª ´Ù¸¥ À̹°Áú¿¡ ¹ÝÀÀÇÏ¿© »ý¼ºÇϴ õ¿¬ Ç×ü¸¦ ¸ð¹æÇϵµ·Ï ¼³°èµÈ ½ÇÇè½Ç¿¡¼­ »ý»êµÈ ºÐÀÚÀÔ´Ï´Ù.

½ÃÀå ¿ªÇÐ :

¾Ï, ÀÚ°¡¸é¿ªÁúȯ µî µ¿¹°ÀÇ ¸¸¼ºÁúȯÀÇ À¯º´·üÀÌ Áõ°¡Çϸ鼭 mAbs¿Í °°Àº Ç¥ÀûÄ¡·áÁ¦ ¹× ƯÀÌÀû Ä¡·áÁ¦ÀÇ Ã¤ÅÃÀÌ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. »ý¸í°øÇÐ ¹× À¯Àü°øÇÐÀÇ ¹ßÀüÀ¸·Î mAbs »ý»êÀÌ Çâ»óµÇ¾î º¸´Ù È¿°úÀûÀÌ°í Æ¯¼öÇÑ Ä¡·á¹ýÀ» Á¦°øÇÒ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù. ¼öÀÇ»çµé »çÀÌ¿¡¼­ Àνİú ¼ö¿ëµµ°¡ ³ô¾ÆÁö¸é¼­ ÀÓ»ó½ÃÇè¿¡¼­ ÁÁÀº °á°ú¸¦ ¾ò°Ô µÈ °Íµµ º¸±Þ¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. µ¿¹°¿ë ÀǾàǰ »ê¾÷ÀÇ È®´ë, ¸ÂÃãÇü Ç¥ÀûÄ¡·á¿¡ ´ëÇÑ °ü½É, ¹Ý·Áµ¿¹° Ä¡·áÀÇ ¹ßÀüÀº ÀÌ·¯ÇÑ Ç×ü¿¡ ´ëÇÑ ¼ö¿ä¸¦ ´õ¿í Áõ°¡½Ã۰í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ±ÔÁ¦ ´ç±¹ÀÇ ½ÂÀΰú ¿¬±¸±â°ü°ú Á¦¾à»ç °£ÀÇ Çù·ÂÀº µ¿¹° ÀÇ·á ºÐ¾ß¿¡¼­ mAbÀÇ °³¹ß ¹× Ȱ¿ëÀ» °¡¼ÓÈ­Çϰí ÀÖ½À´Ï´Ù. ±â¼úÀÌ ¼º¼÷ÇÏ°í ºñ¿ëÀÌ °ü¸®Çϱ⠽¬¿öÁü¿¡ µû¶ó ½ÃÀåÀº Áö¼ÓÀûÀ¸·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, µ¿¹°¿¡°Ô »õ·Ó°í Çõ½ÅÀûÀÎ Ä¡·á ¿É¼ÇÀ» Á¦°øÇÕ´Ï´Ù.

ÀÌ Á¶»ç º¸°í¼­´Â Porter's Five Forces ¸ðµ¨, ½ÃÀå ¸Å·Âµµ ºÐ¼® ¹× ¹ë·ùüÀÎ ºÐ¼®À» ´Ù·ì´Ï´Ù. ÀÌ·¯ÇÑ µµ±¸´Â ¾÷°èÀÇ ±¸Á¶¸¦ ¸íÈ®ÇÏ°Ô ÆÄ¾ÇÇÏ°í ¼¼°è ¼öÁØ¿¡¼­ °æÀïÀÇ ¸Å·ÂÀ» Æò°¡ÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. ¶ÇÇÑ, ÀÌ µµ±¸´Â µ¿¹° ÀÇÇп¡¼­ ´ÜŬ·ÐÇ×ü ¼¼°è ½ÃÀå¿¡¼­ °¢ ºÎ¹®À» Á¾ÇÕÀûÀ¸·Î Æò°¡ÇÒ ¼ö ÀÖ½À´Ï´Ù. µ¿¹° ÀÇ·á¿ë ´ÜŬ·ÐÇ×ü »ê¾÷ÀÇ ¼ºÀå°ú µ¿ÇâÀº ÀÌ Á¶»ç¿¡ ´ëÇÑ ÀüüÀûÀÎ Á¢±Ù ¹æ½ÄÀ» Á¦°øÇÕ´Ï´Ù.

Áö¿ªº° ºÐ¼® :

ÀÌ ¼½¼Ç¿¡¼­´Â ºÏ¹Ì, À¯·´, ¾Æ½Ã¾ÆÅÂÆò¾ç, ¶óƾ¾Æ¸Þ¸®Ä«, Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ µ¿¹° ÀÇÇп¡¼­ ´ÜŬ·ÐÇ×ü ½ÃÀåÀÇ ÇöÀç¿Í ¹Ì·¡ ¼ö¿ä¸¦ °­Á¶ÇÏ´Â Áö¿ª Àü¸ÁÀ» ´Ù·ì´Ï´Ù. ¶ÇÇÑ, ÀÌ º¸°í¼­´Â ¸ðµç ÁÖ¿ä Áö¿ªÀÇ °³º° ¿ëµµ ºÎ¹® ¼ö¿ä, ÃßÁ¤ ¹× ¿¹Ãø¿¡ ÃÊÁ¡À» ¸ÂÃß°í ÀÖ½À´Ï´Ù.

¸ÂÃãÇü ¿ä±¸»çÇ×ÀÌ ÀÖ´Â °æ¿ì, ´ç»ç·Î ¿¬¶ô ºÎʵ右´Ï´Ù. ´ç»çÀÇ Á¶»ç ÆÀÀº °í°´ÀÇ ¿ä±¸¿¡ µû¶ó ¸ÂÃãÇü º¸°í¼­¸¦ Á¦°øÇÒ ¼ö ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå ÁÖ¿ä ¿ä¾à

  • ½ÃÀå ÇÏÀ̶óÀÌÆ®
  • ¼¼°è ½ÃÀå ÇöȲ

Á¦3Àå µ¿¹° ÀÇ·á¿ë ´ÜŬ·ÐÇ×ü - ¾÷°è ºÐ¼®

  • ¼­·Ð : ½ÃÀå ¿ªÇÐ
  • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
  • ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ
  • ½ÃÀå ±âȸ
  • ¾÷°è µ¿Çâ
  • PorterÀÇ Five Forces ºÐ¼®
  • ½ÃÀåÀÇ ¸Å·Â ºÐ¼®

Á¦4Àå ¹ë·ùüÀÎ ºÐ¼®

  • ¹ë·ùüÀÎ ºÐ¼®
  • ¿øÀç·á ºÐ¼®
    • ¿øÀç·á ¸®½ºÆ®
    • ¿øÀç·á Á¦Á¶¾÷ü ¸®½ºÆ®
    • ÁÖ¿ä ¿øÀç·á °¡°Ý µ¿Çâ
  • ÀáÀçÀû ¹ÙÀÌ¾î ¸®½ºÆ®
  • ¸¶ÄÉÆÃ Ã¤³Î
    • Á÷Á¢ ¸¶ÄÉÆÃ
    • °£Á¢ ¸¶ÄÉÆÃ
    • ¸¶ÄÉÆÃ Ã¤³Î ¹ßÀü µ¿Çâ

Á¦5Àå ¼¼°èÀÇ µ¿¹° ÀÇ·á¿ë ´ÜŬ·ÐÇ×ü ½ÃÀå ºÐ¼® : µ¿¹° À¯Çüº°

  • µ¿¹° À¯Çüº° °³¿ä
  • ½ÇÀû µ¥ÀÌÅÍ¿Í ¿¹Ãø µ¥ÀÌÅÍ
  • µ¿¹° À¯Çüº° ºÐ¼®
  • °³
  • ±âŸ

Á¦6Àå ¼¼°èÀÇ µ¿¹° ÀÇ·á¿ë ´ÜŬ·ÐÇ×ü ½ÃÀå ºÐ¼® : ¿ëµµº°

  • °³¿ä : ¿ëµµº°
  • ½ÇÀû µ¥ÀÌÅÍ¿Í ¿¹Ãø µ¥ÀÌÅÍ
  • ºÐ¼® : ¿ëµµº°
  • ÇǺΰú
  • ÅëÁõ
  • ±âŸ

Á¦7Àå ¼¼°èÀÇ µ¿¹° ÀÇ·á¿ë ´ÜŬ·ÐÇ×ü ½ÃÀå ºÐ¼® : ÃÖÁ¾»ç¿ëÀÚº°

  • ÃÖÁ¾»ç¿ëÀÚº° °³¿ä
  • ½ÇÀû µ¥ÀÌÅÍ¿Í ¿¹Ãø µ¥ÀÌÅÍ
  • ÃÖÁ¾»ç¿ëÀÚº° ºÐ¼®
  • µ¿¹° º´¿ø
  • ±âŸ

Á¦8Àå ¼¼°èÀÇ µ¿¹° ÀÇ·á¿ë ´ÜŬ·ÐÇ×ü ½ÃÀå ºÐ¼® : Áö¿ªº°

  • Áö¿ªº° Àü¸Á
  • ¼­·Ð
  • ºÏ¹ÌÀÇ ÆÇ¸Å ºÐ¼®
    • °³¿ä, ½ÇÀû°ú ¿¹Ãø
    • ºÎ¹®º°
    • ±¹°¡º°
    • ¹Ì±¹
    • ij³ª´Ù
    • ¸ß½ÃÄÚ
  • À¯·´ÀÇ ÆÇ¸Å ºÐ¼®
    • °³¿ä, ½ÇÀû°ú ¿¹Ãø
    • ºÎ¹®º°
    • ±¹°¡º°
    • ¿µ±¹
    • ÇÁ¶û½º
    • µ¶ÀÏ
    • ÀÌÅ»¸®¾Æ
    • ·¯½Ã¾Æ
    • ±âŸ À¯·´
  • ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ÆÇ¸Å ºÐ¼®
    • °³¿ä, ½ÇÀû°ú ¿¹Ãø
    • ºÎ¹®º°
    • ±¹°¡º°
    • Áß±¹
    • Àεµ
    • ÀϺ»
    • Çѱ¹
    • È£ÁÖ
    • µ¿³²¾Æ½Ã¾Æ
    • ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç
  • ¶óƾ¾Æ¸Þ¸®Ä«ÀÇ ÆÇ¸Å ºÐ¼®
    • °³¿ä, ½ÇÀû°ú ¿¹Ãø
    • ºÎ¹®º°
    • ±¹°¡º°
    • ºê¶óÁú
    • ¾Æ¸£ÇîÆ¼³ª
    • Æä·ç
    • Ä¥·¹
    • ±âŸ ¶óƾ¾Æ¸Þ¸®Ä«
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ ÆÇ¸Å ºÐ¼®
    • °³¿ä, ½ÇÀû°ú ¿¹Ãø
    • ºÎ¹®º°
    • ±¹°¡º°
    • »ç¿ìµð¾Æ¶óºñ¾Æ
    • ¾Æ¶ø¿¡¹Ì¸®Æ®(UAE)
    • À̽º¶ó¿¤
    • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹
    • ±âŸ Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«

Á¦9Àå µ¿¹° ÀÇ·á¿ë ´ÜŬ·ÐÇ×ü ±â¾÷ÀÇ °æÀï ±¸µµ

  • µ¿¹° ÀÇ·á¿ë ´ÜŬ·ÐÇ×ü ½ÃÀå °æÀï
  • ÆÄÆ®³Ê½Ê/Á¦ÈÞ/ÇùÁ¤
  • ÀμöÇÕº´(M&A)
  • ½ÅÁ¦Ç° Ãâ½Ã
  • ±âŸ °³¹ß

Á¦10Àå ±â¾÷ °³¿ä

  • ±â¾÷ Á¡À¯À² ºÐ¼®
  • ½ÃÀå ÁýÁßµµ
  • Zoetis
  • Merck & Co Inc.
  • Elanco
  • Boehringer Ingelheim GmbH
  • Indian Immunologicals Ltd
  • Virbac

Âü°í - ±â¾÷ ÇÁ·ÎÆÄÀϸµ¿¡¼­ À繫 ¼¼ºÎ Á¤º¸ ¹× ÃÖ±Ù °³¹ß ÇöȲÀº ÀÌ¿ë °¡´É ¿©ºÎ¿¡ µû¶ó ´Þ¶óÁö°Å³ª ºñ°ø°³ ȸ»çÀÇ °æ¿ì ´Ù·çÁö ¾ÊÀ» ¼ö ÀÖ½À´Ï´Ù.

LSH 23.08.25

The global demand for Monoclonal Antibodies in Veterinary Health Market is presumed to reach the market size of nearly USD 2741.58 MN by 2030 from USD 718.09 MN in 2022 with a CAGR of 18.23% under the study period 2023 - 2030.

Monoclonal antibodies (mAbs) in veterinary health refer to a type of targeted therapy used in animals to treat various diseases and conditions. These are laboratory-produced molecules designed to mimic the natural antibodies that the immune system produces in response to infections or other foreign substances.

MARKET DYNAMICS:

The prevalence of chronic diseases in animals, such as cancer and autoimmune disorders, is rising, which is driving the adoption of targeted and specific therapies like mAbs. Biotechnology and genetic engineering advancement have also improved the production of mAbs, offering more effective and specialized treatments. Growing awareness and acceptance among veterinarians, coupled with positive outcomes from clinical trials, have contributed to their popularity. The expanding veterinary pharmaceutical industry, focus on personalized and targeted therapies and improved companion animal care have further boosted the demand for these antibodies. Additionally, regulatory approvals and collaborations between research institutes and pharmaceutical companies have accelerated the development and accessibility of mAbs in veterinary health. As the technology matures and costs become more manageable, the market is expected to witness continued growth, offering new and innovative treatment options for animals.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of monoclonal antibodies in veterinary health. The growth and trends of monoclonal antibodies in veterinary health industry provide a holistic approach to this study.

MARKET SEGMENTATION:

This section of the monoclonal antibodies in veterinary health market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Animal Type

  • Dogs
  • Others

By Application

  • Dermatology
  • Pain
  • Others

By End-User

  • Veterinary Hospitals
  • Others

REGIONAL ANALYSIS:

This section covers the regional outlook, which accentuates current and future demand for the Monoclonal Antibodies in Veterinary Health market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Monoclonal Antibodies in Veterinary Health market include Zoetis, Merck & Co, Inc., Elanco, Boehringer Ingelheim GmbH, Indian Immunologicals Ltd, Virbac. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

TABLE OF CONTENTS

1 . PREFACE

  • 1.1. Report Description
    • 1.1.1. Objective
    • 1.1.2. Target Audience
    • 1.1.3. Unique Selling Proposition (USP) & offerings
  • 1.2. Research Scope
  • 1.3. Research Methodology
    • 1.3.1. Market Research Process
    • 1.3.2. Market Research Methodology

2 . EXECUTIVE SUMMARY

  • 2.1. Highlights of Market
  • 2.2. Global Market Snapshot

3 . MONOCLONAL ANTIBODIES IN VETERINARY HEALTH - INDUSTRY ANALYSIS

  • 3.1. Introduction - Market Dynamics
  • 3.2. Market Drivers
  • 3.3. Market Restraints
  • 3.4. Opportunities
  • 3.5. Industry Trends
  • 3.6. Porter's Five Force Analysis
  • 3.7. Market Attractiveness Analysis
    • 3.7.1 Market Attractiveness Analysis By Animal Type
    • 3.7.2 Market Attractiveness Analysis By Application
    • 3.7.3 Market Attractiveness Analysis By End-user
    • 3.7.4 Market Attractiveness Analysis By Region

4 . VALUE CHAIN ANALYSIS

  • 4.1. Value Chain Analysis
  • 4.2. Raw Material Analysis
    • 4.2.1. List of Raw Materials
    • 4.2.2. Raw Material Manufactures List
    • 4.2.3. Price Trend of Key Raw Materials
  • 4.3. List of Potential Buyers
  • 4.4. Marketing Channel
    • 4.4.1. Direct Marketing
    • 4.4.2. Indirect Marketing
    • 4.4.3. Marketing Channel Development Trend

5 . GLOBAL MONOCLONAL ANTIBODIES IN VETERINARY HEALTH MARKET ANALYSIS BY ANIMAL TYPE

  • 5.1 Overview by Animal Type
  • 5.2 Historical and Forecast Data
  • 5.3 Analysis by Animal Type
  • 5.4 Dogs Historic and Forecast Sales by Regions
  • 5.5 Others Historic and Forecast Sales by Regions

6 . GLOBAL MONOCLONAL ANTIBODIES IN VETERINARY HEALTH MARKET ANALYSIS BY APPLICATION

  • 6.1 Overview by Application
  • 6.2 Historical and Forecast Data
  • 6.3 Analysis by Application
  • 6.4 Dermatology Historic and Forecast Sales by Regions
  • 6.5 Pain Historic and Forecast Sales by Regions
  • 6.6 Others Historic and Forecast Sales by Regions

7 . GLOBAL MONOCLONAL ANTIBODIES IN VETERINARY HEALTH MARKET ANALYSIS BY END-USER

  • 7.1 Overview by End-user
  • 7.2 Historical and Forecast Data
  • 7.3 Analysis by End-user
  • 7.4 Veterinary Hospitals Historic and Forecast Sales by Regions
  • 7.5 Others Historic and Forecast Sales by Regions

8 . GLOBAL MONOCLONAL ANTIBODIES IN VETERINARY HEALTH MARKET ANALYSIS BY GEOGRAPHY

  • 8.1. Regional Outlook
  • 8.2. Introduction
  • 8.3. North America Sales Analysis
    • 8.3.1. Overview, Historic and Forecast Data Sales Analysis
    • 8.3.2. North America By Segment Sales Analysis
    • 8.3.3. North America By Country Sales Analysis
    • 8.3.4. United State Sales Analysis
    • 8.3.5. Canada Sales Analysis
    • 8.3.6. Mexico Sales Analysis
  • 8.4. Europe Sales Analysis
    • 8.4.1. Overview, Historic and Forecast Data Sales Analysis
    • 8.4.2. Europe by Segment Sales Analysis
    • 8.4.3. Europe by Country Sales Analysis
    • 8.4.4. United Kingdom Sales Analysis
    • 8.4.5. France Sales Analysis
    • 8.4.6. Germany Sales Analysis
    • 8.4.7. Italy Sales Analysis
    • 8.4.8. Russia Sales Analysis
    • 8.4.9. Rest Of Europe Sales Analysis
  • 8.5. Asia Pacific Sales Analysis
    • 8.5.1. Overview, Historic and Forecast Data Sales Analysis
    • 8.5.2. Asia Pacific by Segment Sales Analysis
    • 8.5.3. Asia Pacific by Country Sales Analysis
    • 8.5.4. China Sales Analysis
    • 8.5.5. India Sales Analysis
    • 8.5.6. Japan Sales Analysis
    • 8.5.7. South Korea Sales Analysis
    • 8.5.8. Australia Sales Analysis
    • 8.5.9. South East Asia Sales Analysis
    • 8.5.10. Rest Of Asia Pacific Sales Analysis
  • 8.6. Latin America Sales Analysis
    • 8.6.1. Overview, Historic and Forecast Data Sales Analysis
    • 8.6.2. Latin America by Segment Sales Analysis
    • 8.6.3. Latin America by Country Sales Analysis
    • 8.6.4. Brazil Sales Analysis
    • 8.6.5. Argentina Sales Analysis
    • 8.6.6. Peru Sales Analysis
    • 8.6.7. Chile Sales Analysis
    • 8.6.8. Rest of Latin America Sales Analysis
  • 8.7. Middle East & Africa Sales Analysis
    • 8.7.1. Overview, Historic and Forecast Data Sales Analysis
    • 8.7.2. Middle East & Africa by Segment Sales Analysis
    • 8.7.3. Middle East & Africa by Country Sales Analysis
    • 8.7.4. Saudi Arabia Sales Analysis
    • 8.7.5. UAE Sales Analysis
    • 8.7.6. Israel Sales Analysis
    • 8.7.7. South Africa Sales Analysis
    • 8.7.8. Rest Of Middle East And Africa Sales Analysis

9 . COMPETITIVE LANDSCAPE OF THE MONOCLONAL ANTIBODIES IN VETERINARY HEALTH COMPANIES

  • 9.1. Monoclonal Antibodies In Veterinary Health Market Competition
  • 9.2. Partnership/Collaboration/Agreement
  • 9.3. Merger And Acquisitions
  • 9.4. New Product Launch
  • 9.5. Other Developments

10 . COMPANY PROFILES OF MONOCLONAL ANTIBODIES IN VETERINARY HEALTH INDUSTRY

  • 10.1. Company Share Analysis
  • 10.2. Market Concentration Rate
  • 10.3. Zoetis
    • 10.3.1. Company Overview
    • 10.3.2. Company Revenue
    • 10.3.3. Products
    • 10.3.4. Recent Developments
  • 10.4. Merck & Co Inc.
    • 10.4.1. Company Overview
    • 10.4.2. Company Revenue
    • 10.4.3. Products
    • 10.4.4. Recent Developments
  • 10.5. Elanco
    • 10.5.1. Company Overview
    • 10.5.2. Company Revenue
    • 10.5.3. Products
    • 10.5.4. Recent Developments
  • 10.6. Boehringer Ingelheim GmbH
    • 10.6.1. Company Overview
    • 10.6.2. Company Revenue
    • 10.6.3. Products
    • 10.6.4. Recent Developments
  • 10.7. Indian Immunologicals Ltd
    • 10.7.1. Company Overview
    • 10.7.2. Company Revenue
    • 10.7.3. Products
    • 10.7.4. Recent Developments
  • 10.8. Virbac
    • 10.8.1. Company Overview
    • 10.8.2. Company Revenue
    • 10.8.3. Products
    • 10.8.4. Recent Developments

Note - in company profiling, financial details and recent development are subject to availability or might not be covered in case of private companies

ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦